AlphAIAlphAI — Financial news for AI agents
investing.comOCT 281 min read$PALI

Palisade Bio doses first patient in ulcerative colitis trial

Palisade Bio Inc. (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, evaluating PALI-2108. The trial aims to enroll 204 patients and has 29 U.S. sites active, with global expansion ongoing. Topline results are expected in Q4 2027. PALI-2108 is an investigational oral PDE4 inhibitor prodrug. The company also conducts a Phase 2 study for Crohn’s disease.

Original reporting
investing.com
Published Oct 28, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PALI
Bullish
medium confidence
Mentioned
$PALI
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PALIBullishLow
01

Why it matters

The first patient dosing marks a key milestone, but the impact on the share price will likely be modest until efficacy data are released.

02

Market read

First‑in‑human dosing is a positive catalyst for a micro‑cap biotech, but limited immediate trading relevance.

03

What to watch

Potential enrollment delays or safety signals could dampen any upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Palisade Bio (NASDAQ:PALI) is a clinical‑stage biotech developing an oral PDE4 inhibitor for inflammatory bowel disease.

Company-level read

Ticker impact

$PALIBullishMedium confidence
Context

Palisade Bio announced the first patient dosing in its Phase 2b ASCENTRA-UC ulcerative colitis trial, a first report of trial initiation.

Expected impact

modest upside as investors price in trial advancement

Evidence & confidence

Early‑stage trial initiation is material for a biotech but does not guarantee near‑term price movement.

Market effects

Sector

Adds to pipeline momentum for ulcerative colitis therapeutics, modestly positive for the IBD biotech space.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minor, as the trial is early‑stage and company is micro‑cap.

Counterpoint

What could challenge this read

Trial start does not guarantee success; investors may wait for data before taking positions.

Key entities

  • company
    Palisade Bio Inc.

    Biotech developer of PALI-2108.

Read at source← All news

StoryPalisade Bio starts Phase 2b testing of ulcerative colitis drug

Related articles

OCT 21
$PALIMedAI 8/10

Oppenheimer reiterates Palisade Bio stock rating on Crohn’s data

Oppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.

investing.com2 min
OCT 20
$PALIMedAI 8/10

Palisade Bio reports early-stage Crohn’s disease trial results

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.

investing.com1 min
OCT 20
$PALIMedAI 9/10

A gut inflammation marker fell 58.8% in five patients after 14 days on Palisade Bio’s experimental drug.

Palisade Bio (PALI) reported that its experimental drug PALI-2108 showed a 58.8% reduction in a gut inflammation marker in five Crohn's disease patients after 14 days. The Phase 1b study also demonstrated endoscopic improvement and reduced intestinal inflammation. The company is advancing Phase 2b studies for ulcerative colitis and initiating a Phase 2a study for Crohn's disease.

stocktitan.net2 min